摘要
目的观察胰岩消方加减联合化疗对晚期胰腺癌患者生存质量及生存期的影响。方法晚期胰腺癌患者64例随机分为治疗组和对照组各32例。两组患者均给予吉西他滨(每次1000mg/m^(2),第1、8天,静脉滴注)和替吉奥(每日总量60mg/m^(2),分两次口服,连续口服14天后停药7天)化疗方案,每3周重复,共治疗2个疗程。治疗组再给予胰岩消方,并根据不同中医证型辨证加减,每日1剂,疗程3个月。采用Karnofsky功能状态评分标准(KPS评分)和以癌症治疗功能评价量表(FACT-G)为基础的生存质量调查问卷评分评价患者生存质量,比较两组患者临床疗效、中位生存期和不良反应发生率。结果两组患者治疗后的KPS评分均较治疗前升高(P<0.05),且治疗组治疗后高于对照组(P<0.05)。两组患者治疗后的生理状况、情感状况、胰腺疾病相关症状3个维度的评分均较治疗前降低(P<0.05),且治疗组治疗后低于对照组(P<0.05)。治疗后,治疗组社会/家庭状况和功能状况2个维度评分较治疗前升高(P<0.05)。治疗组疾病控制率为62.5%,高于对照组的40.6%(P<0.05)。治疗后治疗组中位生存期为7.1个月,高于对照组的5.7个月(P<0.05)。治疗组患者的不良反应发生率为37.5%,低于对照组的75.0%(P<0.05)。结论胰岩消方加减联合化疗治疗晚期胰腺癌具有协同增效作用,可以改善患者的生存质量,提高疾病控制率,延长患者生存期,降低不良反应发生率。
Objective To explore the effect of modified Yi Yan Xiao Formula(胰岩消方加减)combined with chemotherapy on the quality of life and survival time in patients with advanced pancreatic cancer.Methods Sixty-four patients with advanced pancreatic cancer were randomly divided into a treatment group and a control group with 32 cases in each group.Patients in both groups received chemotherapy including intravenous drip of gemcitabine(1000 mg/m^(2) each time on the first and eighth day)and oral administration of tigio(60 mg/m^(2) per day,twice daily,for 14 consecutive days and then stop medication for seven days);the chemotherapy regimen was repeated every 3 weeks as a course for two courses.The treatment group was additionally given modified Yi Yan Xiao Formula adjusted to different TCM syndromes,one dose per day for 3 months.The Karnofsky performance status(KPS)and the functional assessment of cancer therapy-general(FACT-G)were used to evaluate the quality of life of patients,and the clinical effects,median survival time and adverse events rate were assessed and compared between two groups.Results The KPS scores of both groups increased after treatment(P<0.05),and more increase was seen in the treatment group than in the control group(P<0.05).The scores of the three domains of the physiological status,emotional status,and pancreatic disease-related symptoms of both groups significantly decreased after treatment(P<0.05),and more decrease was seen in the treatment group(P<0.05).The scores of the two domains of social/family status and functional status in the treatment group were higher after treatment than those before treatment(P<0.05).The disease control rate in the treatment group was 62.5%,significantly higher than 40.6%in the control group(P<0.05).The median survival time of the treatment group was 7.1 months,which was longer than 5.7 months of the control group(P<0.05).The adverse events rate in the treatment group was 37.5%,significantly lower than 75.0%in the control group(P<0.05).Conclusion Modified Yi Yan
作者
李富龙
李雅南
高方毅
秦艺文
邓玉海
汤瑾
方盛泉
陈启龙
倪红梅
LI Fulong;LI Yanan;GAO Fangyi;QIN Yiwen;DENG Yuhai;TANG Jin;FANG Shengquan;CHEN Qilong;NI Hongmei(Shanghai University of Traditional Chinese Medicine,Shanghai,201203;Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine;Beijing Jingdu Children's Hospital;Weifang Traditional Chinese Hospital,Shandong Province)
出处
《中医杂志》
CSCD
北大核心
2021年第10期887-892,共6页
Journal of Traditional Chinese Medicine
基金
上海中医药大学中医学一流学科科研创新基金项目(30304118177)。
关键词
胰腺癌
胰岩消方
化疗
生存质量
生存期
pancreatic cancer
Yi Yan Xiao Formula(胰岩消方)
chemotherapy
quality of life
survival time
